Furthermore, (ix) ARV-110 with a CRBN ligand and a non-steroidal AR ligand for prostate cancer metastatic (NCT03888612), (x) ARV-471 with a CRBN ligand and an ER ligand for breast cancer (NCT04072952), and (xi) ARV-766 with a VHL ligand and a BRD4 ligand for prostate cancer metastatic (NCT05067140), are in phase 1 and 2 clinical trials. This evidence concerns the gene ESR1 and breast carcinoma.